# EDGAR Filing Document

**Accession Number:** 0001357459
**File Stem:** 0001493152-25-016483
**Filing Date:** 2025-10
**Character Count:** 19670
**Document Hash:** 94d45ce2136baa797416981386f426be
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-016483.hdr.sgml**: 20251001

**ACCESSION NUMBER**: 0001493152-25-016483

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251001

**DATE AS OF CHANGE**: 20251001

**EFFECTIVENESS DATE**: 20251001

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PALISADE BIO, INC.
- **CENTRAL INDEX KEY:** 0001357459
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 522007292
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290644
- **FILM NUMBER:** 251362679

**BUSINESS ADDRESS:**
- **STREET 1:** 7750 EL CAMINO REAL, SUITE 5200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009
- **BUSINESS PHONE:** (858) 704-4900

**MAIL ADDRESS:**
- **STREET 1:** 7750 EL CAMINO REAL, SUITE 5200
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Seneca Biopharma, Inc.
- **DATE OF NAME CHANGE:** 20200127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neuralstem, Inc.
- **DATE OF NAME CHANGE:** 20060324

**As filed with the Securities and Exchange Commission on October 1, 2025.** 

**Registration No. 333-**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-1**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**Palisade Bio, Inc.** 

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **52-2007292** |
| **(State or Other Jurisdiction of<br> Incorporation or Organization)** | **(Primary Standard Industrial<br> Classification Code Number)** | **(I.R.S. Employer<br> Identification Number)** |

---

**Palisade Bio, Inc.** 

**1902 Wright Place, Suite 200**

**Carlsbad, CA 92008** 

**(858) 704-4900** 

**(Address, including zip code, and telephone number, including area code of registrant's principal executive offices)** 

**JD Finley, Chief Executive Officer** 

**Palisade Bio, Inc.** 

**1902 Wright Place, Suite 200**

**Carlsbad, CA 92008** 

**(858) 704-4900** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Jeffrey C. Thacker** | **Michael F. Nertney** |
| **Ryan J. Gunderson**<br> **John E. Maciejewski**<br> **Gunderson Dettmer Stough Villeneuve**<br> **Franklin & Hachigian, LLP**<br> **3570 Carmel Mountain Road, Suite 200**<br> **San Diego, California 92130**<br> **(858) 436-8000** | **Ellenoff Grossman & Schole LLP**<br> **1345 Avenue of the Americas**<br> **New York, New York 10105**<br> **(212) 370-1300** |

---

**Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.** 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File No. 333-290568)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.** 

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

This Registration Statement is being filed pursuant to Rule 462(b) as promulgated under the Securities Act of 1933, as amended, and includes the registration statement facing page, this page, the signature page, an exhibit index and the required opinion and consents solely to register up to an aggregate of $24,518,000 in (i) additional shares of our common stock, par value $0.01 per share (the "common stock"), (ii) pre-funded warrants to purchase shares of our common stock, (iii) warrants to purchase shares of our common stock to be issued to the representative of the underwriters in the offering ("Representative Warrants"); and (iv) shares of common stock underlying the pre-funded warrants and Representative Warrants. The contents of the Registration Statement on Form S-1 (Registration No. 333-290568), as amended, including the exhibits and power of attorney thereto, which was declared effective by the Securities and Exchange Commission on September 30, 2025, are incorporated by reference in this Registration Statement.

The required opinions and consents are listed on the Exhibit Index attached hereto and are filed herewith.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **<u>Exhibit<br> Number</u>** | **<u>Description of document</u>** |
| 5.1 | [Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.](ex5-1.htm) |
| 23.1 | [Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm.](ex23-1.htm) |
| 23.2 | [Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).](ex5-1.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to the signature page of the Prior Registration Statement on Form S-1 (File No. 333-290568), filed with the Securities and Exchange Commission on September 29, 2025 and incorporated herein by reference).](https://www.sec.gov/Archives/edgar/data/1357459/000149315225015872/forms-1.htm) |
| 107 | [Filing Fee Table.](ex107.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carlsbad, State of California on October 1, 2025.

---

| | |
|:---|:---|
| **Palisade Bio, Inc.** | **Palisade Bio, Inc.** |
| By: | */s/ J.D. Finley*<br>|
|  | J.D. Finley |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY** 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ J.D. Finley* | Chief Executive Officer and Director | October 1, 2025 |
| J.D. Finley | *(Principal Executive Officer)* |  |
| */s/ J. D. Finley* | Chief Financial Officer | October 1, 2025 |
| J.D. Finley | *(Principal Financial Officer and Principal Accounting Officer)* |  |
| \* | Chairman of the Board and Director | October 1, 2025 |
| Donald A. Williams |  |  |
| \* | Director | October 1, 2025 |
| Binxian Wei |  |  |
| \* | Director | October 1, 2025 |
| Emil Chuang |  |  |

---

---

| | |
|:---|:---|
| \*By: | */s/ J.D. Finley* |
|  | J.D. Finley |
|  | Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

October 1, 2025

Palisade Bio, Inc.

1902 Wright Place, Suite 200

Carlsbad, CA 92008

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the sale by Palisade Bio, Inc., a Delaware corporation (the "***Company***"), of up to an aggregate of (A) (i) $23,000,000 worth of shares of the Company's Common Stock, par value $0.01 per share (the "***Shares***"), or (ii) Pre-Funded Warrants to purchase $23,000,000 worth shares of the Company's Common Stock, with an exercise price of $0.0001 per warrant (the "***Pre-Funded Warrants***") and the shares of Common Stock issuable upon exercise thereof (in each case, including up to $3,450,000 of Shares or Pre-Funded Warrants which may be sold pursuant to the exercise of an option granted by the Company to the underwriters) and (B) warrants to purchase up to $1,518,000 worth of shares of Common Stock being issued to Ladenburg Thalmann & Co. Inc., the representative of the underwriters of the offering (the "***Representative Warrants***") and the shares of Common Stock issuable upon exercise thereof, pursuant to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission pursuant to Rule 462(b) of Regulation C promulgated (the "***Registration Statement***"). The Registration Statement incorporates by reference the Registration Statement on Form S-1 (No. 333-290568), which was declared effective on September 30, 2025 (the "***Prior Registration Statement***"), including the prospectus which forms a part of the Prior Registration Statement. We understand that the Shares and/or Pre-Funded Warrants are to be sold to the underwriters for resale to the public as described in the Registration Statement and pursuant to an underwriting agreement, substantially in the form filed as an exhibit to the Prior Registration Statement, to be entered into by and among the Company and the underwriters (the "***Underwriting Agreement***").

In connection with this opinion, we have examined and relied upon the Registration Statement and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. With your consent, we have relied upon certificates and other assurances of officers of the Company as to factual matters without having independently verified such factual matters. We have assumed the genuineness and authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies thereof and the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof.

This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act of 1933, as amended (the "***Act***"), and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as expressly stated herein with respect to the issue of the Shares, Pre-Funded Warrants and Representative Warrants, as the case may be. Our opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. Our opinion herein is expressed solely with respect to the federal laws of the United States and the General Corporation Law of the State of Delaware. Our opinion is based on these laws as in effect on the date hereof, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. We are not rendering any opinion as to compliance with any federal or state antifraud law, rule or regulation relating to securities, or to the sale or issuance thereof.

Subject to the foregoing and the other matters set forth herein, it is our opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;1. When
 the Shares to be issued and sold by the Company are issued and paid for in accordance with
 the terms of the Underwriting Agreement, such Shares will be validly issued, fully paid and
 nonassessable.

2. When
 the Pre-Funded Warrants and Representative Warrants to be issued and sold by the Company
 are issued and paid for in accordance with the terms of the Underwriting Agreement, the Pre-Funded
 Warrants and Representative Warrants will be validly issued and will constitute valid and
 binding obligations of the Company, enforceable against the Company in accordance with their
 terms.

3. The
 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and Representative
 Warrants, when issued and paid for by the Company upon exercise of the Pre-Funded Warrants
 or Representative Warrants, as the case may be, in accordance with the terms of the Pre-Funded
 Warrants or Representative Warrants, as the case may be, will be validly issued, fully paid
 and nonassessable.

Our opinion that the Pre-Funded Warrants and Representative Warrants constitute legal, valid and binding obligations is qualified as to:

&nbsp;&nbsp;&nbsp;&nbsp;a) limitations
 imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent conveyance, moratorium
 or other laws relating to or affecting the rights of creditors generally;

b) rights
 to indemnification and contribution, which may be limited by applicable law or equitable
 principles; and

c) general
 principles of equity, including without limitation concepts of materiality, reasonableness,
 good faith and fair dealing, and the possible unavailability of specific performance or injunctive
 relief and limitation of rights of acceleration, regardless of whether such enforceability
 is considered in a proceeding in equity or at law.

We consent to the reference to our firm under the caption "Legal Matters" in the prospectus included in the Registration Statement and to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Securities and Exchange Commission thereunder.

---

| |
|:---|
| Sincerely, |
| /s/ Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP |
| GUNDERSON DETTMER STOUGH VILLENEUVE FRANKLIN & HACHIGIAN, LLP<br>|

---

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-1 of Palisade Bio, Inc. filed pursuant to Rule 462(b) under the Securities Act of 1933 of our report dated March 24, 2025, relating to the consolidated financial statements, which includes an explanatory paragraph relating to the Company's ability to continue as a going concern.

/s/ Baker Tilly US, LLP

New York, New York

October 1, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Tables**

**Form S-1**

(Form Type)

**Palisade Bio, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br> Type | Security Class Title | Fee<br> Calculation<br> or Carry<br> Forward<br> Rule | Amount<br> Registered | Proposed<br> Maximum<br> Offering<br> Price Per<br> Unit | Maximum<br> Aggregate<br> Offering<br> Price(1)(2)(3) | Fee Rate | Amount of<br> Registration<br> Fee(7) |
| Fees to Be Paid | Equity | Shares of Common Stock, par value $0.01 per share(4) | 457(o) |  |  | $23000000 | 0.00013810 | $3176.30 |
| Fees to Be Paid | Equity | Pre-funded warrants(4)(5) | 457(g) |  |  | Included above |  |  |
| Fees to Be Paid | Equity | Shares of Common Stock issuable upon exercise of pre-funded warrants(4) | 457(o) |  |  | Included above |  |  |
| Fees to Be Paid | Equity | Representative Warrants(5) | 457(g) |  |  |  |  |  |
| Fees to Be Paid | Equity | Shares of Common Stock issuable upon exercise of Representative Warrants(6) | 457(o) |  |  | $1518000 | 0.00013810 | $209.64 |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts |  | $24518000 |  | $3385.94 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid |  |  |  |  |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $3385.94 |

---

(1) Estimated
 solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended
 (the "Securities Act"). Represents only the additional dollar amount of securities being registered and includes the
 additional dollar amount of securities that the underwriters have the option to purchase to cover over-allotments, if any. Does not
 include the securities that the registrant previously registered on the registration statement on Form S-1 (File No. 333-290568).

(2) Pursuant
 to Rule 416 under the Securities Act, the securities registered hereby also include an indeterminate number of additional securities
 as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations, or other similar transactions.

(3) Includes
 the price of additional shares of Common Stock that may be issued upon exercise of the option granted to the underwriter to cover
 over-allotments, if any.

(4) The proposed maximum aggregate offering price of the common stock will
be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed
maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis
based on the offering price of any common stock issued in the offering. Accordingly, the proposed maximum aggregate offering price of
the additional common stock and pre-funded warrants (including the common stock issuable upon exercise of such pre-funded warrants) being
registered hereby, if any, is $23,000,000.

(5) No
 additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.

(6) The
 registrant has agreed to issue upon the closing of this offering, warrants to Ladenburg Thalmann & Co. Inc. entitling it to purchase
 up to 4.0% of the aggregate shares of common stock sold in this offering. The exercise price of the warrants is equal to 165% of
 the public offering price of the common stock offered hereby. As estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457(o) under the Securities Act, the proposed maximum aggregate offering price of the Representative Warrants is $1,518,000,
which is equal to 165% of $920,000 (4% of $23,000,000).

(7) The
 Registrant previously paid aggregate filing fees of $19,349.54 in connection with a previous filing of its registration statement
 on Form S-1 (File No. 333-290568).